From the Editor

Faced with divisive political and social issues, Congress must find a way to reach consensus.

Amid debate about “fake news,” peer-review papers offer vital, objective insight.

New reports address biopharma’s leading concerns: funding for drug development and pricing of finished drugs.

New study will reveal bio/pharma practices and performance on quality issues.

Philadelphia plays host to the exhibits, conferences, and networking activities of CPhI North America on May 16-18, 2017.

Drug type, potential sales, and ownership factor in the race to get drugs to market.

Reducing regulatory roadblocks requires more than the stroke of a pen.

Report: Global medicine spending will reach nearly $1.5 trillion by 2021.

Questions about new healthcare policies, investments, drug approvals, and more will test Biopharma.

Rookie API developers beat pharma at its own game.

CPhI Pharma Award winners were recognized for sweating the details for the bigger picture.

BioPharm International editors seek bioprocessing experts to contribute technical articles in 2017.

Steep price increases for a popular drug have created patient and Congressional backlash.

Congressional partisanship creates noise, but no funding for Zika virus research.

CPhI Pharma Awards seek nominations for excellence in biopharma development and manufacturing.

Advances in single-use systems, consumables, and continuous manufacturing show steady progress.

Proven science-based strategies can help to accelerate vaccine development.

Thought leaders tackle drug shortages and biomanufacturing challenges.

Report: Biologics contribute to rebirth of biopharma innovation.

Infrastructure and payer decisions will determine drug choices in emerging and developed regions.

Biopharma employees in different market segments note subtle differences in job satisfaction.

Biopharma and contract providers must tread carefully amid changing market dynamics.

FDA notes progress in drug development, but cites scientific and funding roadblocks.

As biopharma enjoys success, it cannot ignore pressing patient access questions.

Objective, peer-reviewed papers and technical articles can help advance biopharmaceutical development.